Citalopram (As Hydrobromide)
- Citalopram (As Hydrobromide)
- No Brand Name
- Tablet
- 20mg
- Blister
- 20 / 30 / 100 Tablets
-
• Depression
Mechanism of Action
Inhibits the reuptake of serotonin in presynaptic neurons
Pharmacokinetics
Bioavailability: 80%
Peak serum time: 1-6 hr (4 hr average)
Onset: 1-4 weeks, full response may not be seen until 8-12 weeks after initiating treatment
Excretion: Urine (10%)
Contraindications
• Hypersensitivity
• Coadministration with Pimozide
Adverse Reactions
Nausea, Somnolence, Insomnia, Xerostomia, Increased sweating, Tremor Diarrhea, Ejaculation disorder, Rhinitis, Upper respiratory infection, Dyspepsia, Fatigue, Vomiting, Anxiety, Anorexia, Abdominal pain, Agitation, Impotence, Sinusitis, Dysmenorrhea, Decreased libido, Yawning, Arthralgia, Myalgia, Amenorrhea, Confusion, Cough, Flatulence, Increased saliva, Migraine, Orthostatic hypotension, Paresthesia, Polyuria, Pruritus, Rash, Tachycardia, Weight change
Major Drug Interactions
Dronedarone - Fluconazole - Goserelin - Isocarboxazid - Leuprolide - Mavorixafor - Phenelzine - Pimozide - Procarbazine - Selegiline - Tranylcypromine - Ziprasidone
Warnings
• Not FDA approved for the treatment of bipolar disorder
• This drug is not FDA approved for use in pediatric patients
Recommendations for Patient
-
Pregnancy Considerations
Category: C
Breastfeeding Considerations
Infants receive citalopram in breastmilk and it is detectable in low levels in the serum of some. Monitor the infant for excess drowsiness, restlessness, irritability, poor feeding and poor weight gain, especially in younger, exclusively breastfed infants and when using combinations of psychotropic drugs.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Inhibits the reuptake of serotonin in presynaptic neurons
Pharmacokinetics
Bioavailability: 80%
Peak serum time: 1-6 hr (4 hr average)
Onset: 1-4 weeks, full response may not be seen until 8-12 weeks after initiating treatment
Excretion: Urine (10%)
Contraindications
• Hypersensitivity
• Coadministration with Pimozide
Adverse Reactions
Nausea, Somnolence, Insomnia, Xerostomia, Increased sweating, Tremor Diarrhea, Ejaculation disorder, Rhinitis, Upper respiratory infection, Dyspepsia, Fatigue, Vomiting, Anxiety, Anorexia, Abdominal pain, Agitation, Impotence, Sinusitis, Dysmenorrhea, Decreased libido, Yawning, Arthralgia, Myalgia, Amenorrhea, Confusion, Cough, Flatulence, Increased saliva, Migraine, Orthostatic hypotension, Paresthesia, Polyuria, Pruritus, Rash, Tachycardia, Weight change
Major Drug Interactions
Dronedarone - Fluconazole - Goserelin - Isocarboxazid - Leuprolide - Mavorixafor - Phenelzine - Pimozide - Procarbazine - Selegiline - Tranylcypromine - Ziprasidone
Warnings
• Not FDA approved for the treatment of bipolar disorder
• This drug is not FDA approved for use in pediatric patients
Recommendations for Patient
-
Pregnancy Considerations
Category: C
Breastfeeding Considerations
Infants receive citalopram in breastmilk and it is detectable in low levels in the serum of some. Monitor the infant for excess drowsiness, restlessness, irritability, poor feeding and poor weight gain, especially in younger, exclusively breastfed infants and when using combinations of psychotropic drugs.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people